{"id":"NCT00838110","sponsor":"Pfizer","briefTitle":"A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease","officialTitle":"A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2009-02-06","resultsPosted":"2013-02-08","lastUpdate":"2018-12-06"},"enrollment":742,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Dimebon","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Dimebon","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dimebon 20 mg TID (Cohort 1)","type":"EXPERIMENTAL"},{"label":"Placebo TID (Cohort 1)","type":"PLACEBO_COMPARATOR"},{"label":"Dimebon 20 mg TID (Cohort 2)","type":"EXPERIMENTAL"},{"label":"Placebo TID (Cohort 2)","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multi-center, randomized, double-blind placebo-controlled safety study conducted in 2 study cohorts. In Cohort 1, subjects with Alzheimer's disease (n=250) will receive Dimebon 20 mg or placebo TID for 26 weeks. In Cohort 2 AD subjects (n=500) will be treated with Dimebon 20 mg or placebo TID for 12 weeks After completion of the randomized portion of the study, subjects in both Cohorts will have the opportunity to enroll in a Dimebon open label extension study.","primaryOutcome":{"measure":"Percentage of Participants With Abnormal Clinically Significant Vital Signs in Cohort 1","timeFrame":"Baseline up to Week 30 (follow-up)","effectByArm":[{"arm":"Dimebon (Cohort 1)","deltaMin":0.8,"sd":null},{"arm":"Placebo (Cohort 1)","deltaMin":1.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":118,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1451027"]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":370},"commonTop":["Urinary tract infection","Fall","Fatigue","Somnolence","Headache"]}}